C4 Imaging develops medical devices that enable clinicians to more accurately perform image-guided procedures. The company’s core proprietary technology, C4, has been developed as the first commercially available Positive-Signal MRI Marker.
With over 25 years of experience in commercial leadership roles in the medical device and life sciences industries, Mr. Bright has been involved in the launch of some of the most successful products in the prostate brachytherapy market in both the US and Europe. He now leads C4 Imaging with the objective of ensuring that the successful commercialization of the company's core MRI technology brings clinical utility to physicians and ultimately improves care for the patients they treat.
Previously, Mr. Bright was Vice President, Global Sales and Marketing, and Vice President, Brachytherapy, at Oncura (A GE Healthcare business). He is an Applied Biology graduate of the University of Greenwich in London, UK.
In addition to his role as Founder and Chief Medical Officer, Dr. Frank is a Professor, Radiation Oncology, Deputy Division Head, Strategic Programs and Medical Director, Proton Therapy Center at the University of Texas MD Anderson Cancer Center (UTMDACC). He is also the head of their Prostate Brachytherapy program. He is the President of the American Brachytherapy Society, serves on the editorial board for the International Journal of Brachytherapy, and is an associate senior editor for the parent journal for the field of radiation oncology, the International Journal of Radiation Oncology, Biology, and Physics. He has served as the quality assurance expert for prostate brachytherapy for national cooperative group clinical trials in prostate brachytherapy funded by the National Institutes of Health and National Cancer Institute, and he is the quality assurance brachytherapy expert for the MD Anderson Physicians Network.
Dr. Frank has given numerous presentations nationally and internationally providing oversight for the development of prostate brachytherapy programs. He has recognized the problems inherent in the quality of prostate brachytherapy that led to the development of the C4 technology at MD Anderson. He has received extensive peer reviewed funding including the NIH/NCI, Prostate Cancer Foundation, the UTMDACC, and the Texas Ignition Fund.
Dr. Frank is a graduate of the University of Pennsylvania and entered the naval nuclear propulsion program in 1991. He served as a Submarine Officer on the fast-attach nuclear submarine, U.S.S. Batfish (SSN-681), and completed his active duty service in 1996 as a Lieutenant. Dr. Frank earned his medical degree at Emory University School of Medicine in 2000, completed his residency in Radiation Oncology at the University of Texas MD Anderson Cancer Center, and has been on the MD Anderson faculty since 2005. Dr. Frank is the author of more than 100 peer-reviewed scientific publications and a national and international recognized expert in prostate brachytherapy.
Currently the Chief Technology Officer at C4 Imaging, Dr. Martirosyan is also Professor of Physics and Associate Dean for Research and Educational Innovations at the University of Texas Rio Grande Valley. By applying his extensive experience in bioengineering, nanotechnology and implantable device fabrication, his primary role is to oversee the development of the company’s novel MRI Marker technology.
Dr. Martirosyan received his PhD from the Russian Academy of Sciences, and has since held faculty positions at SEUA and the University of Houston in Texas. Dr. Martirosyan has been awarded a Faculty Fellowship at the Air Force Research Lab three times and serves as Editor-in-Chief of the Journal of OA Nano-Bio-Technology and on the Editorial Boards of the Journal of Nanomedicine and Nanotechnology, International Journal of SHS and Journal of Nanoparticles. He has also participated at numerous National Science Foundation panel meetings. He has been the principal investigator and co-investigator for several Federal (NIH, NSF, AFRL) and State funded research projects and his work has resulted in more than 120 research papers, 5 patents and over 150 presentations at national and international conferences.